Pharmaceutical

AstraZeneca to invest $2.5bn in R&D centre in China

AstraZeneca has announced a $2.5bn investment to establish the company’s sixth worldwide strategic R&D centre in China.

Mar 25, 2025 - 06:00
AstraZeneca to invest $2.5bn in R&D centre in China
AstraZeneca has announced a $2.5bn investment to establish the company’s sixth worldwide strategic R&D centre in China.
Read the original article

Tags:

Previous Article

FDA approves IND application for Everest’s cancer vaccine

Next Article

J&J boosts US operations with $55bn investment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Lilly’s Kisunla does not demonstrate “good value” for UK’s NHS

Lilly’s Kisunla does not demonstrate “good value” for U...

Oct 24, 2024

Erasca’s ERAS-801 gains FDA orphan drug designation for glioblastoma

Erasca’s ERAS-801 gains FDA orphan drug designation for...

Jun 23, 2023

STAT+: Evelo Biosciences, a microbiome company launched by Flagship, shuts down

STAT+: Evelo Biosciences, a microbiome company launched...

Nov 23, 2023